Welcome to our dedicated page for Xtacy Therapeutics news (Ticker: GWSFF), a resource for investors and traders seeking the latest updates and insights on Xtacy Therapeutics stock.
Xtacy Therapeutics Corp. (GWSFF) is a prospect generator assisting high growth companies in the wellness consumer products market. The company recently settled debt by issuing 2,361,500 common shares to creditors, reducing liabilities and improving financial position. With a focus on global wellness, psychedelics, mycology, hemp, and CBD, Xtacy provides financial, operational, and management support to healthcare-related target companies. The securities issued in the debt settlement are subject to a statutory hold period of four months plus a day from the date of issuance. Visit the website for more information.
Next Frontier Pharmaceuticals' subsidiary Benuvia has partnered with Global Wellness Strategies and Shanti Therapeutics to enter the psychedelic drug development market. Benuvia, based in Texas, has a facility permitted by the U.S. DEA and registered with the FDA, specializing in synthetic cannabinoids and psychedelic APIs. The agreement focuses on MDMA, with Benuvia providing life cycle management services, toxicology, and clinical trial assistance. This move is expected to enhance the company’s position in the mental health treatment sector.
FAQ
What is the market cap of Xtacy Therapeutics (GWSFF)?
What does Xtacy Therapeutics Corp. do?
How did Xtacy settle its debt?
What is the focus of Xtacy Therapeutics Corp.?
Are the securities issued in the debt settlement subject to any hold period?
When will the Shares for Debt Transaction close?
Where can I find more information about Xtacy Therapeutics Corp.?
How can I contact Meris Kott, the CEO of Xtacy Therapeutics Corp.?
Is Xtacy listed on any stock exchanges?
What is the former name of Xtacy Therapeutics Corp.?
What type of businesses does Xtacy support?
